Rare kidney disease research on the international stage
Work from the National Registry of Rare Kidney Diseases (RaDaR) will be presented across the 2026 Congress of the European Renal Association (ERA) in Glasgow, including work from research fellows and statisticians.
Dr Katie Wong, RaDaR Clinical Research Fellow at the UK Renal Registry, will present work on Alport syndrome, examining associations between genotype, proteinuria and kidney outcomes using longitudinal UK registry data. Her abstract has been recognised within the ERA Top and Best Abstracts selection as one of the Best Abstracts presented by young authors.
5 June, 16:00-17:00, M1 Room
RaDaR data will also feature in a session led by Dr Lexy Sorrell, RaDaR Statistician, “Real-world clinical profile, treatment patterns and outcomes associated with C3G and primary IC-MPGN: insights from the UK RaDaR registry”.
4 June, 11:15-12:45, Forth Room
In addition, Dr Sapna Shah will present “The Financial and Environmental Cost of Post-Kidney Transplant CMV Infection in the UK”. This work includes significant contributions from RaDaR Biostatistician David Pitcher, reflecting the role of the RaDaR team in supporting robust analysis across kidney research.
4 June, 16:00-17:00, Focussed Oral Room 11
Obstetric registrar Dr Anangsha Kumar will present "The Impact of Kidney Disease on Female Reproductive Health: A Qualitative Study of 710 Women within the RaDaR Registry". Her abstract has also been recognised in the ERA Top and Best Abstracts selection as one of the Best Abstracts presented by young authors.
4 June, 11:27-11:33, Focussed Oral Room 12
Together, these presentations demonstrate the breadth of research enabled by RaDaR, from rare disease characterisation to outcomes research and health economics. Their presence across multiple sessions at ERA 2026 also highlights the growing international relevance of UK registry-led research and its role in informing clinical practice, shaping services and supporting the development of new treatments.